Your browser doesn't support javascript.
Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort.
Di Micco, Pierpaolo; Russo, Vincenzo; Carannante, Novella; Imparato, Michele; Rodolfi, Stefano; Cardillo, Giuseppe; Lodigiani, Corrado.
  • Di Micco P; Internal Medicine Unit, Fatebenefratelli Hospital, 80123 Naples, Italy.
  • Russo V; Cardiology Unit, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli"-Monaldi Hospital, piazzale Ettore Ruggeri, 80131 Naples, Italy.
  • Carannante N; First Division of Infectious Diseases, Cotugno Hospital, 80131 Naples, Italy.
  • Imparato M; Internal Medicine Unit, Fatebenefratelli Hospital, 80123 Naples, Italy.
  • Rodolfi S; Department of Medical Sciences, Humanitas University, 20090 Milan, Italy.
  • Cardillo G; Medylab, Biochimica avanzata Laboratory, 81030 Lusciano (CE), Italy.
  • Lodigiani C; Department of Medical Sciences, Humanitas University, 20090 Milan, Italy.
J Clin Med ; 9(5)2020 May 07.
Article in English | MEDLINE | ID: covidwho-197466
ABSTRACT

INTRODUCTION:

A novel highly pathogenic human coronavirus able to induce severe acute respiratory syndrome (SARS) has been recently recognized as the cause of the coronavirus disease 2019 (COVID-19) outbreak, which has spread rapidly from China to other countries. Little is known about laboratory prognostic markers in COVID-19 patients. The aim of our study was to describe the basic clotting parameters in COVID-19 patients and their prognostic role in different clinical forms of the disease. MATERIAL AND

METHODS:

We enrolled 67 COVID-19 patients admitted to the Emergency Department. A cohort of 67 age- and sex-matched non-COVID-19 patients with acute respiratory illness was used as a control group. For all patients, platelet count (PLT), prothrombin time (PT), activated thromboplastin time (aPTT), C-reactive protein (PCR), fibrinogen, and D-dimer were determined. The COVID-19 population was divided in two groups according to the presence or absence of SARS. The clotting factors values were compared between the groups.

RESULTS:

At admission, the COVID-19 patients showed statistically significant increased levels of fibrinogen (601.5 (480-747) vs. 455 (352.5-588.5) mg/dL; p = 0.0000064), and a higher percentage of patients had fibrinogen levels >400 mg/dL (86% vs.58%; p = 0.0054) compared to the control group. The levels of fibrinogen were higher in COVID-19 patients with SARS compared to those without SARS (747 (600.0-834.0) vs. 567 (472.5-644.50); p = 0.0003).

CONCLUSION:

Fibrinogen seems to increase early in COVID-19 patients and may be used as a risk stratification marker for the early detection of a subgroup of COVID-19 patient at increased risk to develop SARS, who might benefit from a different and thorough clinical surveillance and treatment.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2020 Document Type: Article Affiliation country: JCM9051371

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2020 Document Type: Article Affiliation country: JCM9051371